Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Letetresgene autoleucel - Adaptimmune

X
Drug Profile

Letetresgene autoleucel - Adaptimmune

Alternative Names: GSK 794; GSK-3377794; NY-ESO SPEAR T-cell therapy - GlaxoSmithKline; NY-ESO TCR therapeutic; NY-ESO-1 T cell receptor; NY-ESO-1 TCR T; NY-ESO-1-specific T-cells - Adaptimmune; NY-ESO-1/LAGE-1-modified T-cells; NY-ESO-1c259T; NY-ESO-1c259-antigen-specific-T-cell-receptor-gene-therapy; NY-ESO-1c259-modified-T-cells; NY-ESO-1c259-TCR-transduced-lymphocytes; NY-ESO-1c259-TCR-transduced-T-cells; NY-ESO-c259T

Latest Information Update: 21 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adaptimmune
  • Developer Adaptimmune; GlaxoSmithKline; Merck & Co
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Synovial sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Gastrointestinal cancer; Liposarcoma; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Synovial sarcoma
  • No development reported Liver cancer; Prostate cancer

Most Recent Events

  • 21 Mar 2024 Adaptimmune Therapeutics plans to launch letetresgene autoleucel for the treatment of synovial sarcoma and liposarcoma in the US in 2026 (IV)
  • 01 Dec 2022 GlaxoSmithKline and Merck & Co terminates a phase I/II trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in Canada, Spain, Netherlands due to feasibility issues (IV) (NCT03709706) (EudraCT2018-003949-42)
  • 01 Dec 2022 GlaxoSmithKline and Merck & Co terminates a phase I/II trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Canada, Spain, Netherlands due to feasibility issues (IV) (NCT03709706) (EudraCT2018-003949-42)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top